This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hansel, B. Articles by Kontush, A. Search for Related Content PubMed PubMed Citation Articles by Hansel, B. Articles by Kontush, A.

Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity

Dyslipoproteinemia and Atherosclerosis Research Unit (B.H., P.G., E.N., S.C., E.B., M.J.C., A.K.), National Institute for Health and Medical Research, Institut National de la Santé et de la Recherche Médicale (INSERM); and Service d’Endocrinologie-Metabolisme (P.G., E.B.), Hôpital de la Pitié, 75013 Paris, France

Address all correspondence and requests for reprints to: Dr. Anatol Kontush, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 551, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 boulevard de l’Hôpital, 75651 Paris Cedex 13, France. E-mail kontush{at}chups.jussieu.fr.

A metabolic syndrome (MetS) phenotype is characterized by insulin-resistance, atherogenic dyslipidemia, oxidative stress, and elevated cardiovascular risk and frequently involves subnormal levels of high-density lipoprotein (HDL) cholesterol. We evaluated the capacity of physicochemically distinct HDL subfractions from MetS subjects to protect low-density lipoprotein against oxidative stress.

MetS subjects presented an insulin-resistant phenotype, with central obesity and elevation in systolic blood pressure and plasma triglyceride, LDL-cholesterol, apolipoprotein B, glucose, and insulin levels. Systemic oxidative stress, assessed as plasma 8-isoprostanes, was significantly higher (3.7-fold) in MetS subjects (n = 10) compared with nonobese normolipidemic controls (n = 11). In MetS, small, dense HDL3a, 3b, and 3c subfractions possessed significantly lower specific antioxidative activity (up to –23%, on a unit particle mass basis) than their counterparts in controls. In addition, HDL2a and 3a subfractions from MetS patients possessed lower total antioxidative activity (up to –41%, at equivalent plasma concentrations). The attenuated antioxidative activity of small, dense HDL subfractions correlated with systemic oxidative stress and insulin resistance and was associated with HDL particles exhibiting altered physicochemical properties (core triglyceride enrichment and cholesteryl ester depletion).

We conclude that antioxidative activity of small, dense HDL subfractions of altered chemical composition is impaired in MetS and associated with elevated oxidative stress and insulin resistance. Induction of selective increase in the circulating concentrations of dense HDL subfractions may represent an innovative therapeutic approach for the attenuation of high cardiovascular risk in MetS.

This article has been cited by other articles:

				P. Giral, N. Jacob, C. Dourmap, B. Hansel, A. Carrie, E. Bruckert, X. Girerd, and M. J. Chapman Elevated Gamma-Glutamyltransferase Activity and Perturbed Thiol Profile Are Associated With Features of Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 587 - 593. [Abstract] [Full Text] [PDF]

				K.-L. Chien, M.-F. Chen, H.-C. Hsu, W.-T. Chang, T.-C. Su, Y.-T. Lee, and F. B. Hu Plasma Uric Acid and the Risk of Type 2 Diabetes in a Chinese Community Clin. Chem., February 1, 2008; 54(2): 310 - 316. [Abstract] [Full Text] [PDF]

				J. M. Catov, L. M. Bodnar, R. B. Ness, S. J. Barron, and J. M. Roberts Inflammation and Dyslipidemia Related to Risk of Spontaneous Preterm Birth Am. J. Epidemiol., December 1, 2007; 166(11): 1312 - 1319. [Abstract] [Full Text] [PDF]

				N. Echahidi, D. Mohty, P. Pibarot, J.-P. Despres, G. O'Hara, J. Champagne, F. Philippon, P. Daleau, P. Voisine, and P. Mathieu Obesity and Metabolic Syndrome Are Independent Risk Factors for Atrial Fibrillation After Coronary Artery Bypass Graft Surgery Circulation, September 11, 2007; 116(11_suppl): I-213 - I-219. [Abstract] [Full Text] [PDF]

				L. Persegol, B. Verges, P. Gambert, and L. Duvillard Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation J. Lipid Res., June 1, 2007; 48(6): 1396 - 1401. [Abstract] [Full Text] [PDF]

				N. Sanossian, J. L. Saver, M. Navab, and B. Ovbiagele High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment Stroke, March 1, 2007; 38(3): 1104 - 1109. [Abstract] [Full Text] [PDF]

				R. Asleh, R. Miller-Lotan, M. Aviram, T. Hayek, M. Yulish, J. E. Levy, B. Miller, S. Blum, U. Milman, C. Shapira, et al. Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo Circ. Res., December 8, 2006; 99(12): 1419 - 1425. [Abstract] [Full Text] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				H. Matsui, T. Shimosawa, Y. Uetake, H. Wang, S. Ogura, T. Kaneko, J. Liu, K. Ando, and T. Fujita Protective Effect of Potassium Against the Hypertensive Cardiac Dysfunction: Association With Reactive Oxygen Species Reduction Hypertension, August 1, 2006; 48(2): 225 - 231. [Abstract] [Full Text] [PDF]

				B. Verges, J. M. Petit, L. Duvillard, G. Dautin, E. Florentin, F. Galland, and P. Gambert Adiponectin Is an Important Determinant of ApoA-I Catabolism Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1364 - 1369. [Abstract] [Full Text] [PDF]

				R. H Knopp and P. Paramsothy Oxidized LDL and abdominal obesity: a key to understanding the metabolic syndrome Am. J. Clinical Nutrition, January 1, 2006; 83(1): 1 - 2. [Full Text] [PDF]

				A. Fortuno, G. San Jose, M. U. Moreno, O. Beloqui, J. Diez, and G. Zalba Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome Diabetes, January 1, 2006; 55(1): 209 - 215. [Abstract] [Full Text] [PDF]

				P. Sjogren, S. Basu, M. Rosell, A. Silveira, U. de Faire, B. Vessby, A. Hamsten, M.-L. Hellenius, and R. M. Fisher Measures of Oxidized Low-Density Lipoprotein and Oxidative Stress Are Not Related and Not Elevated in Otherwise Healthy Men With the Metabolic Syndrome Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2580 - 2586. [Abstract] [Full Text] [PDF]

				J. C. Frisbee Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R307 - R316. [Abstract] [Full Text] [PDF]

				J. Chapman Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F56 - F62. [Abstract] [Full Text] [PDF]

				N. Ishizaka, Y. Ishizaka, E.-I. Toda, R. Nagai, and M. Yamakado Association Between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1038 - 1044. [Abstract] [Full Text] [PDF]

				M.-C. B. Garin, B. Kalix, A. Morabia, and R. W. James Small, Dense Lipoprotein Particles and Reduced Paraoxonase-1 in Patients with the Metabolic Syndrome J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2264 - 2269. [Abstract] [Full Text] [PDF]